Treatment of Female Sexual Dysfunction Due to Dyspareunia with Solid-State Vaginal Laser and Recombinant Platelet-Derived Epidermal Growth Factors: A Viable Possibility?
Metadatos
Afficher la notice complèteEditorial
IMR Press
Materia
Female sexual dysfunction Genitourinary syndrome of menopause Dyspareunia Solid-state vaginal laser Epidermal growth factor
Date
2023-02-08Referencia bibliográfica
Mendoza, N., & Quereda, F. (2023). Treatment of Female Sexual Dysfunction Due to Dyspareunia with Solid-State Vaginal Laser and Recombinant Platelet-Derived Epidermal Growth Factors: A Viable Possibility?. Clinical and Experimental Obstetrics & Gynecology, 50(2), 40. [https://doi.org/10.31083/j.ceog5002040]
Résumé
Objective: To examine the efficacy and safety of non-pharmacological and non-ablative options (or a combination of these) for postmenopausal
dyspareunia. Mechanism: Narrative review on non-pharmacological and non-ablative options (or a combination of these)
for postmenopausal dyspareunia. Findings in Brief: Dyspareunia is the most bothersome symptom of the genitourinary syndrome
of menopause, often complicated by decreased sexual interest and arousal. Solid-state vaginal laser (SSVL) and recombinant plateletderived
epidermal growth factors (RGFs) are new alternatives are new alternatives that improve female sexual dysfunction resulting from
dyspareunia. Conclusions: SSVL is a new alternative the treatment of postmenopausal dyspareunia either alone or in combination with
other alternatives with efficacy and safety similar to the classical options.